Prevalence and Associated Risk Factors of Metformin Use in the Treatment of Type-2 Diabetes Mellitus
Metformin Use in Type-2 Diabetes
DOI:
https://doi.org/10.61919/jhrr.v4i3.1693Keywords:
Type 2 diabetes, metformin, prevalence, risk factors, treatment, BMI, smoking, family history, glycemic control, side effects.Abstract
Background: Type 2 diabetes mellitus (T2DM) is a progressive, lifelong metabolic disease characterized by insulin resistance and elevated blood glucose levels. Metformin is the most common initial therapy of choice for T2DM due to its antihyperglycemic activity, safety, and cardiovascular benefits. However, there is a need to explore the prevalence of metformin use and its associated risk factors, given its widespread use and prescription in diverse populations.
Objective: To assess the proportion and risk factors of metformin use among patients with T2DM attending Jinnah Hospital, Lahore, Pakistan, from March 2024 to October 2024.
Methods: This cross-sectional study employed an observational approach. Data was obtained through patient interviews and hospital record searches. A total of 1,729 patients with T2DM who were receiving metformin participated in the study by answering structured questions.
Results: The findings showed a significant association between smoking and metformin use, with smokers accounting for 45.0% and non-smokers 29.7% of users (OR = 1.45, 95% CI: 1.25–1.69). Patients with a body mass index (BMI) ≥30 (53.5%) had higher metformin use compared to those with a BMI <30 (25.7%) (OR = 1.85, 95% CI: 1.45–2.23). Additionally, older patients exhibited higher odds of belonging to the obese category (OR = 1.53, 95% CI: 1.25–1.89).
Conclusions: This study highlights that metformin, the first-line treatment for T2DM, is widely used and more frequently prescribed to older, obese individuals and smokers. These findings raise important questions for future research, particularly regarding lifestyle modification interventions to improve medication compliance, reduce potential harms, and evaluate the long-term effects of treatment among different patient groups, thereby promoting equitable and effective diabetes management.
Downloads
References
Ikwuka AO, Omoju DI, Mahanera OK. Profiling of Clinical Dynamics of Type 2 Diabetes Mellitus in Patients: A Perspective Review. World J Curr Med Pharm Res. 2023;210–8.
El-Kebbi IM, Bidikian NH, Hneiny L, Nasrallah MP. Epidemiology of Type 2 Diabetes in the Middle East and North Africa: Challenges and Call for Action. World J Diabetes. 2021;12(9):1401.
Bailey CJ. Metformin: Historical Overview. Diabetologia. 2017;60(9):1566–76.
Baker C, Retzik-Stahr C, Singh V, Plomondon R, Anderson V, Rasouli N. Should Metformin Remain the First-Line Therapy for Treatment of Type 2 Diabetes? Ther Adv Endocrinol Metab. 2021;12:2042018820980225.
Kułaczkowska ZM, Wróbel M, Rokicka D, Gąsior M, Strojek K. Metformin in Patients with Type 2 Diabetes Mellitus and Heart Failure: A Review. Endokrynol Pol. 2021;72(2):163–70.
Soumya D, Srilatha B. Late Stage Complications of Diabetes and Insulin Resistance. J Diabetes Metab. 2011;2(9):1000167.
Herman R, Kravos NA, Jensterle M, Janež A, Dolžan V. Metformin and Insulin Resistance: A Review of the Underlying Mechanisms Behind Changes in GLUT4-Mediated Glucose Transport. Int J Mol Sci. 2022;23(3):1264.
Bailey CJ. Metformin: Therapeutic Profile in the Treatment of Type 2 Diabetes. Diabetes Obes Metab. 2024;26:3–19.
Chalidis B, Kitridis D, Givissis P. Insulin Dependence Increases the Risk of Postoperative Complications and Inferior Outcome but Not the Survivorship of Total Joint Arthroplasty Among Diabetic Population: A Systematic Review and Meta-Analysis. Eur J Orthop Surg Traumatol. 2022;32(4):701–9.
Yadav A, Pandey S, Singh A, Gupta A. A Comprehensive Review on Diabetes Mellitus: An Overview. World J Pharm Res. 2021;10(6):1584–96.
Hostalek U, Campbell I. Metformin for Diabetes Prevention: Update of the Evidence Base. Curr Med Res Opin. 2021;37(10):1705–17.
Silva-Tinoco R, Cuatecontzi-Xochitiotzi T, Bernal-Ceballos F, de la Torre-Saldaña V, Galindez-Fuentes A, Castillo-Martínez L. Adherence to Antidiabetic Treatment in Primary Health Care in Individuals with Type 2 Diabetes: A Survey Including Socio-Demographic, Patient-Related, and Clinical Factors. Prim Care Diabetes. 2022;16(6):780–5.
Dahlén AD, Dashi G, Maslov I, Attwood MM, Jonsson J, Trukhan V, Schiöth HB. Trends in Antidiabetic Drug Discovery: FDA-Approved Drugs, New Drugs in Clinical Trials, and Global Sales. Front Pharmacol. 2022;12:807548.
Pradeepa R, Mohan V. Epidemiology of Type 2 Diabetes in India. Indian J Ophthalmol. 2021;69(11):2932–8.
Jahan N, Kauser S, Maruf MM, Ahmad S. Stress and Anxiety Among People with Type 2 Diabetes Mellitus. BIRDEM Med J. 2022;12(2):136–41.
Lazzaroni E, Nasr MB, Loretelli C, Pastore I, Plebani L, Lunati ME, et al. Anti-Diabetic Drugs and Weight Loss in Patients with Type 2 Diabetes. Pharmacol Res. 2021;171:105782.
Guo LX, Liu GE, Chen L, Wang HF, Guo J, Zheng XL, et al. Comparison of Clinical Efficacy and Safety of Metformin Sustained-Release Tablet (II) and Metformin Tablet (Glucophage) in Treatment of Type 2 Diabetes Mellitus. Front Endocrinol. 2021;12:712200.
Top WM, Kooy A, Stehouwer CD. Metformin: A Narrative Review of Its Potential Benefits for Cardiovascular Disease, Cancer, and Dementia. Pharmaceuticals. 2022;15(3):312.
Zavaleta MJC, Yovera JGG, Marreros DMM, Robles LDPR, Taype KR, Gálvez KNS, et al. Diabetic Gastroenteropathy: An Underdiagnosed Complication. World J Diabetes. 2021;12(6):794.
Maranta F, Cianfanelli L, Cianflone D. Glycemic Control and Vascular Complications in Diabetes Mellitus Type 2. Diabetes: From Research to Clinical Practice. 2021;4:129–52.
Han Y, Xie H, Liu Y, Gao P, Yang X, Shen Z. Effect of Metformin on All-Cause and Cardiovascular Mortality in Patients with Coronary Artery Diseases: A Systematic Review and Updated Meta-Analysis. Cardiovasc Diabetol. 2019;18:1–16.
Vieira IH, Barros LM, Baptista CF, Rodrigues DM, Paiva IM. Recommendations for Practical Use of Metformin, a Central Pharmacological Therapy in Type 2 Diabetes. Clin Diabetes. 2022;40(1):97–107.
Mazumder A, Singh A. A Review on Metformin: Clinical Significance and Side Effects. Res J Pharm Technol. 2021;14(11):6179–86.
Dutta S, Shah RB, Singhal S, Dutta SB, Bansal S, Sinha S, et al. Metformin: A Review of Potential Mechanisms and Therapeutic Utility Beyond Diabetes. Drug Des Dev Ther. 2023;1907–32.
Masson W, Lavalle-Cobo A, Lobo M, Masson G, Molinero G. Novel Antidiabetic Drugs and Risk of Cardiovascular Events in Patients Without Baseline Metformin Use: A Meta-Analysis. Eur J Prev Cardiol. 2021;28(1):69–75.
Bouchi R, Sugiyama T, Goto A, Imai K, Ihana-Sugiyama N, Ohsugi M, et al. Retrospective Nationwide Study on Trends in First-Line Antidiabetic Medication for Patients with Type 2 Diabetes in Japan. J Diabetes Investig. 2022;13(2):280–91.
Bellanca CM, Augello E, Di Benedetto G, Burgaletto C, Cantone AF, Cantarella G, et al. Influence of Smoking and Smoking Cessation on Antidiabetic Drug Metabolism: Implications for Medication Efficacy. Front Pharmacol. 2024;15:1406860.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Maha Saleem, Sana Ullah, Muhammad Nawaz, Gohar Shah, Baz Muhammad, Muhammad Imran Khan, Muhammad Abbas Khan, Muhammad Idrees
This work is licensed under a Creative Commons Attribution 4.0 International License.
Public Licensing Terms
This work is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). Under this license:
- You are free to share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material) for any purpose, including commercial use.
- Attribution must be given to the original author(s) and source in a manner that is reasonable and does not imply endorsement.
- No additional restrictions may be applied that conflict with the terms of this license.
For more details, visit: https://creativecommons.org/licenses/by/4.0/.
